




<b>Name</b>	Hidehiro ITONAGA	
<b>Current Position</b>	Associate Professor (Vice Director) Transfusion and Cell Therapy Unit, Nagasaki University Hospital	
<b>Country</b>	Japan	
<b>Major Field</b>	Hematological oncology	

## Educational Background

- Medical Science in Life Science and Radiation Research, Nagasaki University Graduate School, Nagasaki, JAPAN  
*Ph.D. (Doctorate of Medical Science), June 2012*
- Nagasaki University School of Medicine, Nagasaki JAPAN  
*M.D., Mar 2005*

## Professional Experience

- Medical Doctor with 19+ years of experience as a hematologist.
- Floor manager with 6+ years of experience to organize hematopoietic stem cell transplantation and CAR-T therapy.
- Doctor of Philosophy (doctorate of medical science) having an investigation about the genetic and epigenetic alterations in myeloid neoplasms.
- Transfusion and Cell Therapy Unit, Nagasaki University Hospital, Nagasaki, JAPAN  
*Associate Professor (Vice Director), Apr 2023 - Present*
- Department of Hematology, Nagasaki University Hospital, Nagasaki, JAPAN  
*Assistant Professor, Aug 2021 – Mar 2023*
- Sylvester Comprehensive Cancer Center (Stephen D. Nimer Lab), Miller School of Medicine, University of Miami, Miami, FL, USA  
*Post-doctoral researcher, Dec 2018 – July 2021*
- Department of Hematology, Nagasaki University Hospital, Nagasaki, JAPAN  
*Assistant Professor, Apr 2016 – Nov 2018*
- Department of Hematology, Sasebo City general Hospital, Sasebo, JAPAN  
*Medical Staff, June 2012 – Mar 2016*
- Medical Science in Life Science and Radiation Research, Nagasaki University Graduate School, Nagasaki, JAPAN  
*Senior Resident, Apr 2007 – May 2012*
- Department of Internal Medicine, Isahaya General Hospital, Isahaya, JAPAN  
*Junior Resident, Apr 2006 – Mar 2007*
- Department of Internal Medicine, Nagasaki University Hospital, Nagasaki, JAPAN  
*Junior Resident, Apr 2005 – Mar 2006*

## Other Experience and Professional Memberships

Japanese Society of Hematology (Diplomate, Instructor, Councilor)  
Japanese Society for Transplantation and Cellular Therapy (Diplomate, Councilor)  
Japanese Society of Medical Oncology (Diplomate, Instructor)  
The Japan Society of Transfusion Medicine and Cell Therapy (Diplomate)  
The Japanese Society of Internal Medicine (Diplomate, Instructor)  
American Society of Hematology

## Main Scientific Publications

1. Itonaga H, et al. Expression of myeloperoxidase in acute myeloid leukemia blasts mirrors the distinct DNA methylation pattern involving the downregulation of DNA methyltransferase DNMT3B. *Leukemia.*



- 
- 2014;28(7):1459-1466.
2. Itonaga H, et al. Treatment of relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: the Nagasaki Transplant Group experience. *Blood*. 2013;121(1):219-225.
  3. Itonaga H, et al. Allogeneic transplantation of bone marrow versus peripheral blood stem cells from HLA-identical relatives in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukemia: a propensity score analysis of a nationwide database. *Ann Hematol*. 2023;102(5):1215-1227.
  4. Itonaga H, et al. Outcome of therapy-related myelodysplastic syndrome and oligoblastic acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: A propensity score matched analysis. *Hematol Oncol*. 2022;40(4):752-762.
  5. Itonaga H, et al. Clinical impact of the loss of chromosome 7q on outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant*. 2019;54(9):1471-1481.
  6. Itonaga H, et al. Prognostic Impact of Donor Source on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in Adults with Chronic Myelomonocytic Leukemia: A Nationwide Retrospective Analysis in Japan. *Biol Blood Marrow Transplant*. 2018;24(4):840-848.
  7. Itonaga H, et al. Increased opportunity for prolonged survival after allogeneic hematopoietic stem cell transplantation in patients aged 60-69 years with myelodysplastic syndrome. *Ann Hematol*. 2019;98(6):1367-1381.
  8. Itonaga H, et al. Molecular analysis of the BCR-ABL1 kinase domain in chronic-phase chronic myelogenous leukemia treated with tyrosine kinase inhibitors in practice: study by the Nagasaki CML Study Group. *Leuk Res*. 2014;38(1):76-83.
  9. Itonaga H, et al. Characteristic patterns of relapse after allogeneic hematopoietic SCT for adult T-cell leukemia-lymphoma: a comparative study of recurrent lesions after transplantation and chemotherapy by the Nagasaki Transplant Group. *Bone Marrow Transplant*. 2015;50(4):585-591.
  10. Itonaga H, et al. Distinct clinical features of infectious complications in adult T cell leukemia/lymphoma patients after allogeneic hematopoietic stem cell transplantation: a retrospective analysis in the Nagasaki transplant group. *Biol Blood Marrow Transplant*. 2013;19(4):607-615.
  11. Kataoka K, Itonaga H, et al. Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma. *Blood*. 2018;131(2):215-225.
  12. Yoshizato T, Itonaga H, et al. Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. *Blood*. 2017;129(17):2347-2358.
  13. Kataoka K, Itonaga H, et al. Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers. *Nature*. 2016;534(7607):402-406.
  14. Kataoka K, Itonaga H, et al. Integrated molecular analysis of adult T cell leukemia/lymphoma. *Nat Genet*. 2015;47(11):1304-1315.
  15. Makishima H, Itonaga H, et al. Germ line DDX41 mutations define a unique subtype of myeloid neoplasms. *Blood*. 2023;141(5):534-549.
  16. Sawayama Y, Itonaga H, et al. Cytomegalovirus reactivation is associated with increased mortality more than 100 days after allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma. *Am J Hematol*. 2019;94(5):E143-E146.
  17. Ishiyama K, Itonaga H, et al. Graft-versus-MDS effect after unrelated cord blood transplantation: a retrospective analysis of 752 patients registered at the Japanese Data center for Hematopoietic Cell Transplantation. *Blood Cancer J*. 2019;9(3):31.
  18. Itonaga H, et al. Adult T-cell leukemia/lymphoma in donor cells responding to second allogeneic hematopoietic stem cell transplantation using unrelated cord blood: the Nagasaki Transplant Group experience. *Leuk Lymphoma*. 2016;57(12):2946-2948.
  19. Mas G, Itonaga H, Nimer S, et al. The SWI/SNF chromatin remodeling subunit DPF2 facilitates NRF2-dependent anti-inflammatory and anti-oxidant gene expression. *J Clin Invest*. 2023. doi: 10.1172/JCI158419.
  20. Chen C, Itonaga H, Nimer S, et al. Epigenetic and Transcriptional Regulation of Innate Immunity in Cancer. *Cancer Res*. 2022;82(11):2047-2056.
  21. Man N, Itonaga H, Nimer S, et al. p300 suppresses the transition of myelodysplastic syndromes to acute myeloid leukemia. *JCI Insight*. 2021;6(19):e138478.
-